Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.

Cancer discovery - 1 Mar 2015

Li Yan, Chitnis Nilesh, Nakagawa Hiroshi, Kita Yoshiaki, Natsugoe Shoji, Yang Yi, Li Zihai, Wasik Mariusz, Klein-Szanto Andres J P, Rustgi Anil K, Diehl J Alan

Abstract excerpt

UNLABELLED: Protein arginine methyltransferase 5 (PRMT5) has been implicated as a key modulator of lymphomagenesis. Whether PRMT5 has overt oncogenic function in the context of leukemia/lymphoma and whether it represents a therapeutic target remains to be established. We demonstrate that inactivation of PRMT5 inhibits colony-forming activity by multiple oncogenic drivers, including cyclin D1, c-MYC, NOTCH1, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin D1
Share to Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, T-Cell

Share to Lymphoma

Share to Lymphoma, T-Cell

Share to Methylation

Share to Oncogenes

Share to Protein-Arginine N-Methyltransferases

Source

Open in PubMed Open full text

Identifiers

PMID: 25582697
DOI: 10.1158/2159-8290.CD-14-0625
PMCID: PMC4355177

Genes

PRMT5
MYC
NOTCH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.PMID 25582697Read ↗

PRMT5 is required for cell-cycle progression and p53 tumor suppressor function.Semantic proximity Read ↗

PRMT5 supports multiple oncogenic pathways in mantle cell lymphomaSemantic proximity Read ↗

Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformationSemantic proximity Read ↗

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.Semantic proximity Read ↗

Protein arginine-methyltransferase-dependent oncogenesis.Semantic proximity Read ↗

Pan-cancer analysis identifies protein arginine methyltransferases PRMT1 and PRMT5 and their related signatures as markers associated with prognosis, immune profile, and therapeutic response in lung adenocarcinomaSemantic proximity Read ↗

Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerSemantic proximity Read ↗

Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemiaSemantic proximity Read ↗

PRMT5-exacerbating tumor stemness and immunosuppression confer a novel immunotherapeutic vulnerability in aggressive prostate cancerSemantic proximity Read ↗

Protein Arginine Methyltransferase 5 (PRMT5) Mutations in Cancer Cells.Semantic proximity Read ↗

PRMT5 inhibitors actively promote metastatic progression of lung adenocarcinomaSemantic proximity Read ↗

PRMT1 promotes neuroblastoma cell survival through ATF5Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.